Denovo Biopharma Plans To Initiate A Global Phase III Trial Of DLBCL Drug
San Diego/Hangzhou-based Denovo Biopharma plans to launch a biomarker driven global Phase III clinical trial for its lead drug DB102 as a first line treatment for diffuse large B-cell lymphoma (DLBCL) patients this year.